U.S. Markets closed

Alphatec Holdings Inc (ATEC) Files 10-K for the Fiscal Year Ended on December 31, 2018

- By insider

Alphatec Holdings Inc (ATEC) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018. Alphatec Holdings Inc is a medical technology company. It is engaged in the design, development and promotion of products for the surgical treatment of spine disorders. Its product portfolio includes Biolocs, cervical, interbody, and others. Alphatec Holdings Inc has a market cap of $114.510 million; its shares were traded at around $2.65 with and P/S ratio of 0.74.


For the last quarter Alphatec Holdings Inc reported a revenue of $25.3 million, compared with the revenue of $26.28 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $91.7 million, a decrease of 9.9% from the previous year. For the last five years Alphatec Holdings Inc had an average revenue decline of 14.3% a year.

The reported loss per diluted share was $1.2 for the year, compared with the loss per share of $21.53 in the previous year. The Alphatec Holdings Inc had an operating margin of -15.08%, compared with the operating margin of -7.52% a year before. The 10-year historical median operating margin of Alphatec Holdings Inc is -7.85%. The profitability rank of the company is 3 (out of 10).

At the end of the fiscal year, Alphatec Holdings Inc has the cash and cash equivalents of $29.1 million, compared with $22.5 million in the previous year. The company had no long term debt, compared with $37.8 million in the previous year. Alphatec Holdings Inc has a financial strength rank of 4 (out of 10).

At the current stock price of $2.65, Alphatec Holdings Inc is traded at 10.5% discount to its historical median P/S valuation band of $2.96. The P/S ratio of the stock is 0.74, while the historical median P/S ratio is 0.83. The stock lost 15.13% during the past 12 months.

Directors and Officers Recent Trades:

  • Director Donald Allen Williams bought 4,000 shares of ATEC stock on 03/12/2019 at the average price of $2.47. The price of the stock has increased by 7.29% since.
  • EVP, Clinical Strategies Kelli Mari Howell bought 100,000 shares of ATEC stock on 03/11/2019 at the average price of $2.59. The price of the stock has increased by 2.32% since.
  • Director Evan Bakst bought 20,566 shares of ATEC stock on 03/11/2019 at the average price of $2.59. The price of the stock has increased by 2.32% since.

For the complete 20-year historical financial data of ATEC, click here.

This article first appeared on GuruFocus.